Analysis-Obesity market sales potential tightens as Novo and Lilly enter new era

By Maggie Fick, Bhanvi Satija and Mariam Sunny LONDON, Feb 2 (Reuters) - The long-held Wall Street expectation that the global market for obesity drugs would reach $150 billion in the next decade is looking a lot less certain with U.S. prices falling for GLP-1 treatments from Novo Nordisk and Eli Lilly and competition heating up in the cash-pay consumer market. The fast-changing ​landscape, which includes the expected entry of new drugs and generic competition, has led to a recalculation of what the pe ...